OncoMatch/Clinical Trials/NCT06437509
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer
Is NCT06437509 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including BL-B01D1 and PD-1 monoclonal antibody for extensive-stage small-cell lung cancer.
Treatment: BL-B01D1 · PD-1 monoclonal antibody — This study is a phase II clinical study to explore the efficacy and safety of BL-B01D1 + PD-1 monoclonal antibody combination therapy in patients with extensive-stage small cell lung cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage IV
extensive-stage small cell lung cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: antibody-drug conjugate
Exception: with small molecule toxins as topoisomerase I inhibitors
Prior use of ADC drug therapy with small molecule toxins as topoisomerase I inhibitors
Cannot have received: systemic anti-tumor regimen
Exception: for extensive-stage small cell lung cancer
Prior treatment with any systemic anti-tumor regimen for extensive-stage small cell lung cancer
Lab requirements
Blood counts
the organ function level must meet the requirements
Kidney function
the organ function level must meet the requirements
Liver function
the organ function level must meet the requirements
Cardiac function
No severe cardiovascular and cerebrovascular diseases in the first half of the year; no QT interval prolongation, complete left bundle branch block, III degree atrioventricular block, frequent and uncontrollable arrhythmia
the organ function level must meet the requirements; Screening the history of severe cardiovascular and cerebrovascular diseases in the first half of the year ; QT interval prolongation, complete left bundle branch block, III degree atrioventricular block, frequent and uncontrollable arrhythmia
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify